Suppr超能文献

新型非氟喹诺酮类抗生素奈诺沙星对沙眼衣原体和肺炎衣原体的体外活性

In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae.

作者信息

Chotikanatis Kobkul, Kohlhoff Stephan A, Hammerschlag Margaret R

机构信息

Division of Infectious Diseases, Department of Pediatrics, State University of New York Downstate Medical Center, Brooklyn, New York, USA.

出版信息

Antimicrob Agents Chemother. 2014;58(3):1800-1. doi: 10.1128/AAC.02263-13. Epub 2013 Dec 23.

Abstract

The in vitro activities of nemonoxacin, levofloxacin, azithromycin, and doxycycline were tested against 10 isolates each of Chlamydia trachomatis and Chlamydia pneumoniae. The MICs at which 90% of the isolates of both C. trachomatis and C. pneumoniae were inhibited (MIC90s) were 0.06 μg/ml (range, 0.03 to 0.13 μg/ml). The minimal bactericidal concentrations at which 90% of the isolates were killed by nemonoxacin (MBC90s) were 0.06 μg/ml for C. trachomatis (range, 0.03 to 0.125 μg/ml) and 0.25 for C. pneumoniae (range, 0.015 to 0.5 μg/ml).

摘要

对10株沙眼衣原体和10株肺炎衣原体分别测试了奈诺沙星、左氧氟沙星、阿奇霉素和多西环素的体外活性。沙眼衣原体和肺炎衣原体90%的分离株被抑制时的最低抑菌浓度(MIC90)为0.06μg/ml(范围为0.03至0.13μg/ml)。奈诺沙星使90%的分离株被杀死时的最低杀菌浓度(MBC90),对于沙眼衣原体为0.06μg/ml(范围为0.03至0.125μg/ml),对于肺炎衣原体为0.25μg/ml(范围为0.015至0.5μg/ml)。

相似文献

引用本文的文献

2
Atypical pneumonia (Review).非典型肺炎(综述)
Exp Ther Med. 2024 Sep 11;28(5):424. doi: 10.3892/etm.2024.12713. eCollection 2024 Nov.
6
Antibiotics in the clinical pipeline at the end of 2015.2015年末处于临床研发阶段的抗生素
J Antibiot (Tokyo). 2017 Jan;70(1):3-24. doi: 10.1038/ja.2016.72. Epub 2016 Jun 29.
8
Nemonoxacin: first global approval.萘莫沙星:全球首次批准。
Drugs. 2014 Aug;74(12):1445-53. doi: 10.1007/s40265-014-0270-0.
9
Review of nemonoxacin with special focus on clinical development.奈诺沙星综述,特别关注其临床开发情况。
Drug Des Devel Ther. 2014 Jul 5;8:765-74. doi: 10.2147/DDDT.S63581. eCollection 2014.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验